Symbols / KZR
KZR Chart
About
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 49.65M |
| Enterprise Value | -30.80M | Income | -61.70M | Sales | — |
| Book/sh | 11.33 | Cash/sh | 12.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 55 | IPO | — |
| P/E | — | Forward P/E | -2.07 | PEG | — |
| P/S | — | P/B | 0.60 | P/C | — |
| EV/EBITDA | 0.48 | EV/Sales | — | Quick Ratio | 6.89 |
| Current Ratio | 7.07 | Debt/Eq | 11.95 | LT Debt/Eq | — |
| EPS (ttm) | -8.44 | EPS next Y | -3.27 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -31.27% |
| ROE | -56.86% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.32M |
| Shs Float | 5.11M | Short Float | 2.79% | Short Ratio | 5.52 |
| Short Interest | — | 52W High | 6.85 | 52W Low | 3.53 |
| Beta | 0.55 | Avg Volume | 39.79K | Volume | 18.92K |
| Target Price | $6.00 | Recom | None | Prev Close | $6.76 |
| Price | $6.78 | Change | 0.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$6.78
Latest analyst target
3. DCF / Fair value
$-85.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.78
Low
$5.00
High
$7.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-17 | down | Jefferies | Buy → Hold | $7 |
| 2025-10-17 | down | William Blair | Outperform → Market Perform | — |
| 2025-10-17 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2025-07-16 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-19 | main | Wells Fargo | Equal-Weight → Equal-Weight | $9 |
| 2024-12-02 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-14 | main | Wells Fargo | Equal-Weight → Equal-Weight | $11 |
| 2024-10-18 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-10-14 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-10-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-22 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-03-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-11-14 | main | Wells Fargo | Equal-Weight → Equal-Weight | $2 |
| 2023-10-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-10-05 | down | JonesTrading | Buy → Hold | — |
| 2023-09-25 | main | HC Wainwright & Co. | Buy → Buy | $20 |
News
RSS: Latest KZR news- Kezar Life Sciences stock climbs as company seeks strategic alternatives - Investing.com hu, 16 Oct 2025 07
- Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive - Stocktwits Fri, 17 Oct 2025 07
- Wells Fargo Lowers Price Target for KZR Amid Maintained Equal-We - GuruFocus Fri, 17 Oct 2025 07
- All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy - Yahoo Finance Wed, 17 Sep 2025 07
- Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know - Nasdaq Mon, 05 Jan 2026 08
- Kalamazoo Resources Halts Trading Ahead of Capital Raising Announcement - The Globe and Mail Mon, 22 Dec 2025 08
- Kezar Launches Review After FDA Blocks Liver Drug Plans - Kezar Life Sciences (NASDAQ:KZR) - Benzinga Fri, 17 Oct 2025 07
- Breakthrough in Autoimmune Hepatitis: Kezar's Drug Achieves 36% Response Rate While Placebo Shows Zero - Stock Titan ue, 25 Mar 2025 07
- Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq ue, 27 May 2025 07
- William Blair downgrades Kezar Life Sciences stock rating on FDA setback - Investing.com Fri, 17 Oct 2025 07
- KZR: William Blair Downgrades Kezar Life Sciences Rating | KZR S - GuruFocus Fri, 17 Oct 2025 07
- Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation - Stocktwits Fri, 17 Oct 2025 07
- Kezar Life Sciences (KZR) Stock Forecast and Price Target 2026 $KZR - MarketBeat Sat, 11 May 2024 15
- Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire Mon, 28 Oct 2024 07
- Is This Flaming Hot Biotech Stock a Buy? - The Motley Fool ue, 09 Jun 2020 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 561 | 2401 | — | Sale at price 4.28 per share. | SCHILLER MARK C | Chief Operating Officer | — | 2025-07-02 00:00:00 | D |
| 1 | 264 | 1130 | — | Sale at price 4.28 per share. | CHIANG PICHI LUO | Officer | — | 2025-07-02 00:00:00 | D |
| 2 | 6688 | 3879 | — | Sale at price 0.58 per share. | SCHILLER MARK C | Officer | — | 2024-07-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -79.63M | -93.07M | -66.03M | -52.96M |
| TotalUnusualItems | -1.47M | -6.19M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -1.47M | -6.19M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -83.74M | -101.87M | -68.24M | -54.63M |
| ReconciledDepreciation | 1.04M | 1.07M | 1.02M | 1.51M |
| EBITDA | -81.10M | -99.25M | -66.03M | -52.96M |
| EBIT | -82.14M | -100.32M | -67.05M | -54.47M |
| NetInterestIncome | 6.87M | 9.55M | 2.92M | 29.00K |
| InterestExpense | 1.59M | 1.55M | 1.19M | 159.00K |
| InterestIncome | 8.46M | 11.10M | 4.11M | 188.00K |
| NormalizedIncome | -82.27M | -95.68M | -68.24M | -54.63M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -83.74M | -101.87M | -68.24M | -54.63M |
| TotalExpenses | 89.14M | 112.24M | 71.16M | 54.66M |
| TotalOperatingIncomeAsReported | -90.61M | -111.42M | -71.16M | -54.66M |
| DilutedAverageShares | 7.29M | 7.26M | 6.74M | 5.28M |
| BasicAverageShares | 7.29M | 7.26M | 6.74M | 5.28M |
| DilutedEPS | -11.00 | -14.04 | -10.10 | -10.40 |
| BasicEPS | -11.00 | -14.04 | -10.10 | -10.40 |
| DilutedNIAvailtoComStockholders | -83.74M | -101.87M | -68.24M | -54.63M |
| NetIncomeCommonStockholders | -83.74M | -101.87M | -68.24M | -54.63M |
| NetIncome | -83.74M | -101.87M | -68.24M | -54.63M |
| NetIncomeIncludingNoncontrollingInterests | -83.74M | -101.87M | -68.24M | -54.63M |
| NetIncomeContinuousOperations | -83.74M | -101.87M | -68.24M | -54.63M |
| PretaxIncome | -83.74M | -101.87M | -68.24M | -54.63M |
| OtherIncomeExpense | -1.47M | -6.19M | ||
| SpecialIncomeCharges | -1.47M | -6.19M | 0.00 | 0.00 |
| WriteOff | 1.55M | 2.91M | ||
| RestructuringAndMergernAcquisition | -79.00K | 3.28M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | 6.87M | 9.55M | 2.92M | 29.00K |
| InterestExpenseNonOperating | 1.59M | 1.55M | 1.19M | 159.00K |
| InterestIncomeNonOperating | 8.46M | 11.10M | 4.11M | 188.00K |
| OperatingIncome | -89.14M | -105.24M | -71.16M | -54.66M |
| OperatingExpense | 89.14M | 112.24M | 71.16M | 54.66M |
| ResearchAndDevelopment | 65.74M | 85.70M | 51.01M | 38.94M |
| SellingGeneralAndAdministration | 23.39M | 26.54M | 20.15M | 15.72M |
| GeneralAndAdministrativeExpense | 23.39M | 26.54M | 20.15M | 15.72M |
| OtherGandA | 23.39M | 26.54M | 20.15M | 15.72M |
| TotalRevenue | 0.00 | 7.00M | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 7.00M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 7.30M | 7.28M | 6.85M | 5.63M |
| ShareIssued | 7.30M | 7.28M | 6.85M | 5.63M |
| TotalDebt | 16.18M | 18.93M | 21.26M | 14.04M |
| TangibleBookValue | 116.92M | 187.57M | 269.87M | 196.88M |
| InvestedCapital | 127.24M | 197.64M | 279.71M | 206.50M |
| WorkingCapital | 117.16M | 189.21M | 274.73M | 203.44M |
| NetTangibleAssets | 116.92M | 187.57M | 269.87M | 196.88M |
| CapitalLeaseObligations | 5.85M | 8.86M | 11.43M | 4.42M |
| CommonStockEquity | 116.92M | 187.57M | 269.87M | 196.88M |
| TotalCapitalization | 122.03M | 197.64M | 279.71M | 206.50M |
| TotalEquityGrossMinorityInterest | 116.92M | 187.57M | 269.87M | 196.88M |
| StockholdersEquity | 116.92M | 187.57M | 269.87M | 196.88M |
| GainsLossesNotAffectingRetainedEarnings | -162.00K | -130.00K | -923.00K | -291.00K |
| OtherEquityAdjustments | -162.00K | -130.00K | -923.00K | -291.00K |
| RetainedEarnings | -434.50M | -350.76M | -248.89M | -180.65M |
| AdditionalPaidInCapital | 551.57M | 538.46M | 519.62M | 377.76M |
| CapitalStock | 7.00K | 7.00K | 68.00K | 56.00K |
| CommonStock | 7.00K | 7.00K | 68.00K | 56.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 27.77M | 33.66M | 29.70M | 21.06M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.44M | 15.92M | 18.70M | 12.85M |
| LongTermDebtAndCapitalLeaseObligation | 7.44M | 15.92M | 18.70M | 12.85M |
| LongTermCapitalLeaseObligation | 2.33M | 5.85M | 8.87M | 3.22M |
| LongTermDebt | 5.11M | 10.07M | 9.83M | 9.62M |
| CurrentLiabilities | 20.33M | 17.74M | 11.00M | 8.21M |
| OtherCurrentLiabilities | 106.00K | 265.00K | 99.00K | |
| CurrentDebtAndCapitalLeaseObligation | 8.74M | 3.01M | 2.56M | 1.20M |
| CurrentCapitalLeaseObligation | 3.53M | 3.01M | 2.56M | 1.20M |
| CurrentDebt | 5.22M | |||
| OtherCurrentBorrowings | 5.22M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.72M | 3.71M | 3.26M | 1.97M |
| PayablesAndAccruedExpenses | 8.87M | 11.02M | 5.17M | 5.04M |
| CurrentAccruedExpenses | 5.22M | 2.77M | 2.69M | 3.02M |
| Payables | 3.65M | 8.25M | 2.48M | 2.03M |
| AccountsPayable | 3.65M | 8.25M | 2.48M | 2.03M |
| TotalAssets | 144.68M | 221.24M | 299.57M | 217.93M |
| TotalNonCurrentAssets | 7.19M | 14.29M | 13.85M | 6.28M |
| OtherNonCurrentAssets | 134.00K | 674.00K | 282.00K | |
| NonCurrentPrepaidAssets | 674.00K | 5.46M | ||
| NonCurrentAccountsReceivable | 1.74M | |||
| NetPPE | 4.78M | 8.69M | 13.17M | 6.00M |
| AccumulatedDepreciation | -6.45M | -5.42M | -4.60M | -3.65M |
| GrossPPE | 11.22M | 14.11M | 17.77M | 9.65M |
| Leases | 3.49M | 3.49M | 3.37M | 3.27M |
| OtherProperties | 1.89M | 4.78M | 9.74M | 2.71M |
| MachineryFurnitureEquipment | 5.85M | 5.84M | 4.67M | 3.67M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 137.49M | 206.95M | 285.72M | 211.65M |
| OtherCurrentAssets | 351.00K | 251.00K | 920.00K | 729.00K |
| PrepaidAssets | 3.95M | 2.53M | 9.16M | 2.57M |
| Receivables | 938.00K | 2.80M | ||
| OtherReceivables | 514.00K | 2.10M | ||
| AccruedInterestReceivable | 424.00K | 695.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 132.25M | 201.37M | 276.56M | 208.35M |
| OtherShortTermInvestments | 90.50M | 165.88M | 236.10M | 145.47M |
| CashAndCashEquivalents | 41.75M | 35.49M | 40.46M | 62.88M |
| CashEquivalents | 41.14M | 35.35M | ||
| CashFinancial | 609.00K | 144.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -74.24M | -83.45M | -60.42M | -42.75M |
| IssuanceOfDebt | 0.00 | 0.00 | 9.53M | |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 126.54M | 100.97M |
| CapitalExpenditure | -29.00K | -1.81M | -1.58M | -316.00K |
| InterestPaidSupplementalData | 1.33M | 1.31M | 973.00K | 69.00K |
| EndCashPosition | 41.75M | 35.49M | 40.46M | 62.88M |
| BeginningCashPosition | 35.49M | 40.46M | 62.88M | 21.23M |
| EffectOfExchangeRateChanges | -63.00K | -2.00K | -49.00K | -50.00K |
| ChangesInCash | 6.32M | -4.96M | -22.38M | 41.70M |
| FinancingCashFlow | 103.00K | 638.00K | 127.86M | 112.58M |
| CashFlowFromContinuingFinancingActivities | 103.00K | 638.00K | 127.86M | 112.58M |
| ProceedsFromStockOptionExercised | 103.00K | 638.00K | 1.32M | 2.08M |
| NetCommonStockIssuance | 0.00 | 0.00 | 126.54M | 100.97M |
| CommonStockIssuance | 0.00 | 0.00 | 126.54M | 100.97M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 9.53M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 9.53M | |
| LongTermDebtIssuance | 0.00 | 0.00 | 9.53M | |
| InvestingCashFlow | 80.43M | 76.05M | -91.39M | -28.44M |
| CashFlowFromContinuingInvestingActivities | 80.43M | 76.05M | -91.39M | -28.44M |
| NetInvestmentPurchaseAndSale | 80.46M | 77.85M | -89.81M | -28.13M |
| SaleOfInvestment | 171.79M | 258.25M | 242.39M | 128.25M |
| PurchaseOfInvestment | -91.34M | -180.40M | -332.20M | -156.38M |
| NetPPEPurchaseAndSale | -29.00K | -1.80M | -1.58M | -316.00K |
| SaleOfPPE | 0.00 | 5.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -29.00K | -1.81M | -1.58M | -316.00K |
| OperatingCashFlow | -74.21M | -81.64M | -58.85M | -42.44M |
| CashFlowFromContinuingOperatingActivities | -74.21M | -81.64M | -58.85M | -42.44M |
| ChangeInWorkingCapital | -1.30M | 4.71M | -4.46M | 1.23M |
| ChangeInOtherWorkingCapital | -1.67M | -303.00K | -94.00K | -1.04M |
| ChangeInOtherCurrentLiabilities | -94.00K | -1.04M | ||
| ChangeInOtherCurrentAssets | 3.18M | -4.92M | -392.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -3.15M | 6.35M | 1.81M | 1.22M |
| ChangeInPrepaidAssets | 335.00K | 3.58M | -5.79M | 1.05M |
| OtherNonCashItems | 267.00K | 238.00K | 224.00K | 91.00K |
| StockBasedCompensation | 13.01M | 18.14M | 14.01M | 7.60M |
| AssetImpairmentCharge | 1.55M | 2.91M | 0.00 | 0.00 |
| AmortizationOfSecurities | -5.04M | -6.83M | -1.40M | 1.77M |
| DepreciationAmortizationDepletion | 1.04M | 1.07M | 1.02M | 1.51M |
| DepreciationAndAmortization | 1.04M | 1.07M | 1.02M | 1.51M |
| OperatingGainsLosses | 12.00K | |||
| GainLossOnSaleOfPPE | 12.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -83.74M | -101.87M | -68.24M | -54.63M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KZR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|